首页 › 基金 › Paradigm Biocapital Advisors LP › PCVX
Paradigm Biocapital Advisors LP 对 PCVX 的持仓历史
VAXCYTE INC · 医疗保健
Paradigm Biocapital Advisors LP 在 Q3 2026 的 13F 申报中披露持有 PCVX(VAXCYTE INC)2,142,852 股,市值约 US$121.9M,约占其申报组合的 2.42%,在其申报持仓中市值排名第 13 位。 Paradigm Biocapital Advisors LP 最近 11 个申报季度中有 11 个季度披露了 PCVX 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Paradigm Biocapital Advisors LP 对 PCVX 的持仓演变
Paradigm Biocapital Advisors LP 于 Q1 2024 首次披露 PCVX 持仓:1,239,995 股(约 US$84.7M)。 该持仓在 Q1 2026 达到峰值 4,793,020 股,市值约 US$278.5M。 在 11 次申报中,Paradigm Biocapital Advisors LP 7 次增持、3 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 2,142,852 股、市值约 US$121.9M,环比增持 15,000 股。。 持仓曾出现大幅变动:Q3 2024 减持约 56% (随后一个季度股价下跌 28%)、Q4 2024 增持约 414% (随后一个季度股价下跌 54%)、Q2 2025 增持约 99% (随后一个季度股价上涨 11%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 1.24M | $84.70M | 新进 |
| Q2 2024 | 627.20K | $47.36M | 减持 |
| Q3 2024 | 276.80K | $31.63M | 减持 |
| Q4 2024 | 1.42M | $116.47M | 增持 |
| Q1 2025 | 1.70M | $64.06M | 增持 |
| Q2 2025 | 3.37M | $109.65M | 增持 |
| Q3 2025 | 3.78M | $136.33M | 增持 |
| Q4 2025 | 4.07M | $187.70M | 增持 |
| Q1 2026 | 4.79M | $278.52M | 增持 |
| Q2 2026 | 2.13M | $123.69M | 减持 |
| Q3 2026 | 2.14M | $121.93M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PCVX 与 13F 数据
PCVX(VAXCYTE INC)属于医疗保健行业。我们追踪的基金中还有 31 只申报持有 PCVX,申报仓位最大的包括:Jupiter Topco LLC (US$1.04B), 骏利亨德森集团 (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PCVX 的基金
- Jupiter Topco LLC 17.97M 股 · $1.04B · Q2 2026
- 骏利亨德森集团 16.58M 股 · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M 股 · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M 股 · $667.02M · Q2 2026
- Deep Track Capital, LP 3.51M 股 · $199.89M · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 3.28M 股 · $186.60M · Q3 2026
- Kynam Capital Management, LP 2.61M 股 · $148.39M · Q3 2026
- Caligan Partners LP 2.19M 股 · $127.23M · Q2 2026
- Bellevue Group AG 1.97M 股 · $114.63M · Q2 2026
- Maverick 资本 1.61M 股 · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M 股 · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M 股 · $81.11M · Q3 2026
更多关于 Paradigm Biocapital Advisors LP
常见问题
How long has Paradigm Biocapital Advisors LP held PCVX?
Paradigm Biocapital Advisors LP has disclosed PCVX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Paradigm Biocapital Advisors LP's current position in PCVX?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 2.14M shares of PCVX (VAXCYTE INC), valued at $121.93M, representing 2.42% of its reported portfolio and ranking #13.
Has Paradigm Biocapital Advisors LP been buying or selling PCVX?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in PCVX. The position peaked in Q1 2026 at 4.79M shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, 骏利亨德森集团, T. Rowe Price Investment Management, Inc., among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.